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Abstract 
Despite advances in diagnostic technology, significant gaps remain in access to malaria diagnosis. Accurate diagnosis 
and misdiagnosis leads to unnecessary waste of resources, poor disease management, and contributes to a cycle of 
poverty in low-resourced communities. Despite much effort and investment, few new technologies have reached 
the field in the last 30 years aside from lateral flow assays. This suggests that much diagnostic development effort has 
been misdirected, and/or that there are fundamental blocks to introduction of new technologies. Malaria diagnosis is 
a difficult market; resources are broadly donor-dependent, health systems in endemic countries are frequently weak, 
and the epidemiology of malaria and priorities of malaria programmes and donors are evolving. Success in diagnostic 
development will require a good understanding of programme gaps, and the sustainability of markets to address 
them. Targeting assay development to such clearly defined market requirements will improve the outcomes of 
product development funding. Six market segments are identified: (1) case management in low-resourced countries, 
(2) parasite screening for low density infections in elimination programmes, (3) surveillance for evidence of contin-
ued transmission, (4) clinical research and therapeutic efficacy monitoring, (5) cross-checking for microscopy quality 
control, and (6) returned traveller markets distinguished primarily by resource availability. While each of these markets 
is potentially compelling from a public health standpoint, size and scale are highly variable and continue to evolve. 
Consequently, return on investment in research and development may be limited, highlighting the need for poten-
tially significant donor involvement or the introduction of novel business models to overcome prohibitive economics. 
Given the rather specific applications, a well-defined set of stakeholders will need to be on board for the successful 
introduction and scaling of any new technology to these markets.
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Background
Malaria seems ripe for the introduction of new and bet-
ter diagnostic technologies. Despite being preventable, 
detectable and curable, it remains one of the main causes 
of mortality due to infectious disease. People at risk still 
fail to access early and accurate diagnosis, particularly 
in sub-Saharan Africa where the main burden of disease 
persists [1]. Misdiagnosis leads to unnecessary waste of 
resources, poor disease management, and contributes to 
a cycle of poverty in affected communities [2].
Despite advances in various aspects of diagnostic tech-
nology development, no new diagnostics have gained 
wide traction or a significant commercial market since 
the introduction of rapid diagnostic tests (RDTs) based 
on lateral flow formats in the early 1990s, which now 
dominate the point of care testing (POCT) market [3]. 
In spite of deficiencies in implementation, malaria diag-
nosis has improved dramatically over the last decade, 
albeit from a very low base, and RDT roll-out enabled the 
World Health Organization (WHO) recommendation 
in 2010 on universal parasite-based diagnosis. Reported 
diagnostic testing in the public sector in sub-Saharan 
Africa, for example, has increased from 36  % of sus-
pected malaria cases tested in 2005 to 65 % tested in 2014 
(after the WHO recommendations), with RDTs account-
ing for 71  % of diagnostic tests [4]. However, this also 
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demonstrates that a considerable gap persists, impacting 
both malaria control and prospects for elimination.
Arguments for universal, parasite-based diagnosis 
are clear. Increasing use of lateral flow rapid diagnostic 
tests has provided poorly resourced, malaria endemic 
populations with access to diagnoses of similar accuracy 
to that available in hospitals in more developed health 
systems. This technology, when well used, is transform-
ing fever management, has reformed understanding of 
malaria transmission, and has made malaria elimination 
look achievable [5]. Good malaria diagnosis also provides 
countries with the information necessary to target anti-
malaria resources to communities that would most ben-
efit and enables donors to measure the impact of funding. 
There is, therefore, a clear public health case for expand-
ing and improving malaria diagnosis, either through cur-
rent or new diagnostic platforms.
To understand how to address the remaining and wide 
diagnostic gap, it is necessary to understand where the 
gap is purely technological, and where it is the result of 
other factors, such as health systems financing, human 
resources and logistics, or simple disinterest. As fund-
ing for diagnostic product development is small in total 
[6], resources for product development must be directed 
to where there is real need and clear potential benefit. 
Research and development funding should have a good 
chance of achieving a useful public health outcome, and 
provide developers and manufacturers access to a suf-
ficient market to justify their investment. This requires 
concentration on technologies that have characteristics 
that address identifiable and significant gaps, or offer 
significant advantages over the often low-cost, effective 
technologies already in use.
Priorities for malaria diagnostics have progressed sig-
nificantly over recent years with renewed emphasis on 
tools required for malaria elimination. The transition of 
many countries traditionally considered to be high bur-
den to a low-transmission state makes local or regional 
elimination potentially achievable [7]. Diagnostic 
requirements to address this situation have been divided 
elsewhere into two spheres:
  • Tools to guide case management of acute fever [8, 9].
  • Tools to guide and achieve elimination [8, 9].
While this dichotomy is broadly useful in guiding 
thinking on implementation, it encompasses a range 
of specific epidemiological contexts and programmatic 
needs and is insufficient to delineate the types of tests 
that are necessary to implement these quite different 
strategies. This paper categorizes diagnostic markets 
according to their role in overall malaria management, 
and the specific performance characteristics required to 
address them. The malaria diagnostic market is broken 
into six distinct markets, or use-cases, to which prospec-
tive technologies can be applied:
1. Case management (in low-resourced endemic coun-
tries).
2. Parasite screening (for low-density infections in elim-
ination programmes).
3. Population screening (surveys for evidence of contin-
ued transmission).
4. Clinical research and therapeutic efficacy monitor-
ing.
5. Microscopy quality control (cross-checking for light 
microscopy).
6. Non-endemic country (returned traveller) markets, 
distinguished primarily by resource availability.
By segmenting the market into areas with clearly dif-
fering requirements and resources, a framework is 
developed for identifying diagnostic needs based on epi-
demiologic setting (Fig.  1) and minimum requirements 
for market entry. Such an approach could help to reduce 
the apparent redundancy seen in the current develop-
ment of malaria diagnostics, and move the field forward 
more efficiently.
These variable requirements for malaria diagnostic tests 
in different market segments can be codified in target 
product profiles (TPPs) that specify the device require-
ments necessary to perform an identified task. Some 
performance parameters of TPPs are essential, some are 
desirable, and the importance of some will vary in differ-
ent settings. The principles underlying the TPPs for the 
six markets suggested in this discussion are addressed in 
the following sections and summarized in Table  1. The 
detailed TPPs outlined in Additional file 1: Annex S1 are 
intended as examples of each identified market. They are 
derived from the MalERA TPPs developed in 2012–2013 
[8], but adapted to the market segmentation suggested 
here. Other TPPs are being developed elsewhere and 
requirements change with time in response to evolving 
epidemiology and programme priorities.
Detection of parasitaemia in endemic settings
Case management in low resources endemic countries
Requirements
Case management requires assays that are supportable in 
a near-patient setting (typically POCT), minimize patient 
waiting time, and are low cost. The primary requirement 
for parasite detection is a sensitivity sufficient to detect 
symptomatic infections that are likely to have significant 
clinical consequences (morbidity or mortality), with a 
high reliability in confirmation of absence of malaria 
infection as a cause of illness (specificity). The capacity 
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to detect parasite densities above a threshold of 100–200 
parasites/µL appears sufficient in most cases of clini-
cal Plasmodium falciparum infection [13]. However, the 
required lower limit of detection (LLOD) may be lower 
for diagnosis of clinical Plasmodium vivax infection 
[8, 9, 14, 15]. While identifying and treating infections 
with parasite densities below 100 parasites/µL is clearly 
desirable from an elimination point of view, i.e. reducing 
overall transmission [16], it could be argued that distin-
guishing infections likely to be responsible for symptoms 
from low density infections that are likely to be incidental 
to current illness holds some advantage in promoting the 
identification of other non-malarial causes of fever.
Case management diagnostic tools must provide suffi-
cient immediate information to guide appropriate treat-
ment. In  situations where various Plasmodium species 
occur with different treatment requirements, tests must 
differentiate between species (principally P. falciparum 
and P. vivax). It is, however, difficult to quantify the accu-
racy required in species differentiation when develop-
ing TPPs. In case management, specific identification of 
P. vivax and Plasmodium ovale may be desirable for epi-
demiological purposes, but not necessary for managing 
the acute episode. In most areas of sub-Saharan Africa, 
mono-infections with non-P. falciparum species are rela-
tively unusual and detection of P. falciparum alone can 
be sufficient [1], but where only non-falciparum species 
are endemic (e.g. areas of east Asia), it is still highly desir-
able to retain capacity to detect P. falciparum as severe 
cases may occur in non-immune returned travellers 
or their secondary cases. Therefore, capacity to detect 
P. falciparum is essential in most cases, while discrimi-
nation of other species in case management depends on 
species prevalence, co-infection patterns, and available 
resources.
Tools in current use
Endemic population case management is clearly the larg-
est application of malaria diagnostic technologies, with 
the largest public health impact. While access to diagno-
sis is still low compared to potential need, an estimated 
197 million microscopy tests were performed and at 
least 160 million RDTs distributed to National Malaria 
Control Programmes in 2014 (probably a large under-
estimate as manufacturers report over 300 million sales) 
[4]. Light microscopy and RDTs, when of good quality, 
Parasite prevalence 
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Fig. 1 The importance of six malaria diagnostic markets in different epidemiological settings. As parasite prevalence declines (left to right), estima-
tion of transmission becomes more dependent on low limit of detection screening and survey assays. Slide cross-checking and research markets 
cut across endemic and non-endemic settings
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are adequate to detect most cases of clinically-significant 
malaria [13], and can be used successfully on a broad 
scale [17].
In use since the 1990s, lateral flow antigen-detecting 
assays (known as RDTs) can provide an accurate diagno-
sis for case management with a similar analytical LLOD 
to microscopy when in good condition and prepared and 
interpreted correctly, and are more amenable to remote 
locations and less dependent on high skill levels [18]. 
Currently, RDTs are available at well below US$0.50, are 
relatively stable in field conditions, provide some poten-
tial for species differentiation, and are adaptable to a vil-
lage health worker level within the health system [19, 20]. 
RDTs can reach an LLOD sufficient for safe case manage-
ment of P. falciparum [21–27], though sensitivity may 
still be insufficient for non-falciparum parasites [8, 9, 14, 
15]. However, RDTs are not quantitative (which is of only 
limited importance in case management), species differ-
entiation is limited, and quality control at point of use is 
difficult, placing the patient at risk due to manufacturing 
or storage failure [28].
While most RDTs have targeted histidine-rich pro-
tein-2 (HRP2) as a marker for P. falciparum infection, 
parasite populations have long been recognized with 
HRP2 gene deletions in the Amazon, undetectable by 
these tests [29]. Rising frequency of HRP2 gene deletions 
in African countries, recognized but unpublished at time 
of writing, raise the need for tests for non-HRP2 falcipa-
rum-specific targets (e.g. lactate dehydrogenase), though 
this will involve improving current technology rather 
than new platform introduction.
The persistence of light microscopy for malaria over a 
century after its introduction arises partly from its labo-
ratory versatility across sample types and diseases, and 
from an absence of practical alternatives for applications, 
such as parasite quantitation and species differentiation 
[30]. While harder to support and less adaptable to com-
munity-level use, field microscopy has similar potential 
in terms of cost and throughput, and is useful for disease 
management beyond malaria. However, its dependence 
on technician performance can result in poor reproduc-
ibility [31–34], making the technology poorly suited to 
clinical decision-making in many settings where malaria 
is endemic. Its entrenched position, both in terms of 
microscopes in use and established commodity sup-
ply chains, means that it is likely to remain in wide use 
at some levels of the health system for the foreseeable 
future, despite the advent and increasing use of RDTs.
In view of the various deficiencies of current tests and 
the persisting large unreached at-risk population, signifi-
cant unaddressed diagnostic gaps do persist that retard 
case management in regions where most cases occur [1]. 
There has been a continuing technological and program-
matic failure in filling this gap, and an increase in funding 
and interest in product development over recent years 
has failed to produce successful replacement technolo-
gies. To be widely applicable in this market, a test will 
need to at least match the current performance of RDTs 
Table 1 Examples of minimum target product profiles and market size
All values are dependent on program capacity and epidemiological setting
O optimum, M minimum
a Refer to Additional file 1: Annex S1 for exceptions and further details
b If we assume 4 sites per country, in around 50 endemic countries that actually run them. On top of that, around 50 research studies each year
c Based on unpublished estimates done by the authors using data from the World Malaria Report 2012 and 2013
d Based on unpublished estimates by the authors using data from Askling et al. [72]
Cost per processed sample (USD) LLOD Market size
Case management (O): ≤$1.00
(M): ≤$1.00
(O) < 5 p/µL (elimination)
(M) 100–200 p/µL
171 million slides examined via microscopy [10]
Parasite screening (O): ≤$1.00
(M): ≤$5.00
(O) ≤ 2 p/µLa
(M) < 20 p/µL
(LAMP, PCR achieve 1–2 p/µL)
~33 million people (within low-prevalence infection 
foci. Conservative estimate) [11]. Potential 1.5–8 
million tests each year
Population screening (O): ≤$1.00
(M): ≤$5.00
(O) ≤ 2 p/µLa
(M) < 20 p/µL
(LAMP, PCR achieve 1–2 p/µL)
7000–10,000 cases surveyed [12]
Research/drug monitoring Depends on application (O) ≤ 5 p/µL (ex: drug trials)a
(M) ≤ 5 p/µL (ex: drug trials)a
Approximately 250 TES sites (~50/100 countries actu-
ally conducting TES). Numbers for wider research 
market unclearb
Microscopy quality control (O): ≤$1.00
(M): ≤$1.00
(O): < 10 p/µL
(M): 50 p/µL
29 million slides cross‐checkedc
Non-endemic countries (O): ≤$1.00
(M): ≤$5.00
(O) ≤ 2 p/µLa
(M) < 20 p/µL
(LAMP, PCR achieve 1–2 p/µL)
30,000 suspected cases (screens) in USA. 200,000 
suspected cases in Western Europed
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and good microscopy and equal them in terms of sim-
plicity of use (RDTs) and cost. The failure of successful 
alternatives to emerge for malaria case management sug-
gests that this is a technologically difficult barrier to over-
come, and health system innovation may be at least as 
important a technology innovation to address this con-
tinued need.
Parasite screening for low‑density infections in elimination 
programmes
Progress towards elimination has highlighted the inad-
equacies of current field assays for specific applications 
such as screening and surveillance [35]. This is a relatively 
new market, and focal screen and treat (FSAT) strategies 
are not well established in most malaria endemic coun-
tries [36]. The place of screening relative to other strat-
egies also remains the subject of debate. However, there 
is broad consensus that low-cost, highly-sensitive and 
specific screening tools would benefit malaria elimina-
tion in many countries currently endemic for malaria 
[8], whether as an adjunct to, or a driver of, elimination 
programmes.
The uses of diagnostic tests in elimination strategies, 
including their required performance and the strategies 
surrounding their use, are not well defined. Individuals 
with little previous exposure to parasites can maintain 
blood stage P. falciparum infection for up to 12 months 
or more, and be asymptomatic much of that time [37–
43]. During the course of infection, parasite density will 
frequently be below the LLOD for expert microscopy [37, 
38, 40, 44–46] and may be below the LLOD of routine 
polymerase chain reaction (PCR) leading to reservoirs of 
infection that remain undetected. Peaks in parasite den-
sity associated with fever could bring the patient to the 
attention of health services and aid diagnosis [37, 38, 47], 
but much of the infection course will remain hidden from 
routine case management diagnostic tools [16, 37, 38], 
leaving infectious individuals to promote transmission 
(Fig. 2) [48]. Light microscopy and RDTs may detect only 
a quarter of all cases. There is thus a need for low-cost 
highly sensitive field tests in low transmission settings 
targeting elimination [49]. Screening with these tools is, 
therefore, expected to be of limited use.
Leaving aside discussions on the relative impact of 
screening versus a combination of intensive vector man-
agement, case detection and mass drug administration 
(MDA), there is demand for near-patient screening tests 
capable of identifying asymptomatic cases with low-
density infections in elimination programmes (e.g. FSAT 
programmes) [36, 46], and in border screening to protect 
transmission-free areas [50]. It seems likely that a mix of 
FSAT and MDA strategies will be used in elimination set-
tings and tailored to the requirements of local epidemiol-
ogy and resources.
To be widely applicable, such screening tests will need 
to have LLOD sufficiently low to detect a substantial and 
predictable proportion of asymptomatic infections. The 
LLOD necessary to achieve this is unclear and probably 
Thresholds of good RDT /microscopy 
PCR/LAMP 








Person may infect mosquitoes and transmit infecon 
through all of this period 
Fig. 2 Stylized time course of an untreated Plasmodium falciparum infection in a host, and the impact of varying thresholds of detection on assay 
positivity. Red bars represent episodes of fever. Derived from observations of controlled infections to induce fever in tertiary syphilis patients, com-
piled by Collins and Jeffreys, US CDC. Unpublished data
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varies by epidemiological setting. A test with a LLOD of 
1–2 parasites/µL can more than double detection rates 
compared with RDTs or microscopy [16]. As parasite 
density drops further, the probability of transmission 
from these infections will be smaller [16, 51], though this 
varies with time [38]. The importance of these infections 
to transmission also varies with the factors responsible 
for reducing local transmission in the first place, be they 
bed net use, access to case management, human behav-
iour, house construction, vector habits, or environmental 
change. MalERA recommended an LLOD of ≤5 parasite/
µL as an optimum [8]. Detection of less than 2 parasite/
µL, similar to nested PCR, is achievable now with loop-
mediated isothermal amplification (LAMP) in near-
patient settings [52].
An effective screening tool in an elimination setting 
will need to provide a result rapid enough to enable rapid 
treatment of parasite positive cases. The assay will need 
to distinguish between species in most geographical loca-
tions to provide information to guide treatment. Near-
patient operability is desirable, though not essential if 
the screening test is used for broad population surveys to 
determine foci of transmission. Rapid results are of high 
importance to FSAT strategies to reduce both the likeli-
hood that patient contact will be lost prior to treatment, 
and the likelihood of further onward transmission before 
treatment (elimination of P. vivax and P. ovale liver stage). 
A low false-positive rate is important, as assay results 
are likely to be used to determine parasite prevalence 
and not just guide directed treatment. As parasite preva-
lence in asymptomatic populations with relatively stable 
low transmission will be low, high specificity is difficult 
to achieve. However, overtreatment in this context is not 
directly harmful, assuming anti-malarials with few side 
effects are used.
Surveillance for evidence of continued transmission
Malaria programs are required to identify areas with a 
high probability of ongoing transmission and areas where 
it is highly probable that transmission has ceased. Such 
evidence informs decisions on deployment of resources 
at the national and community levels. There is likely to 
be an increasing demand for surveillance, or population 
screening, as elimination programs progress and trans-
mission becomes increasingly heterogeneous, requir-
ing data to guide resource allocation and FSAT or MDA 
interventions and to aid confirmation of elimination. The 
market for population screening tools is characterized 
by a requirement to determine the probability of ongo-
ing transmission and the lack of requirement for immedi-
ate treatment (desirable, but not clinically imperative in 
asymptomatic cases).
Two methods may be used to establish a high probabil-
ity of continuing transmission: identification of current 
infection in members of a population, or identification of 
evidence of recent infection. While detection of parasi-
taemia is concrete evidence that prevalence is above zero, 
asymptomatic low-density parasite carriage can occur 
at very low prevalence in the population [40, 46]. Detec-
tion requires tools with very low LLOD and sampling of a 
very high proportion of the population in order to detect 
the few current cases. Sampling for a persistent marker 
of recent infection reduces specificity (in terms of cur-
rent infection) but samples a wider temporal window and 
so should provide greater sensitivity with a lower sample 
size. The immediate candidate biomarkers are host anti-
bodies specific to the malaria parasite [53–56]. Ideally, 
such antibodies would have relatively short half-lives, 
and so indicate infections within a defined time period. 
Screening based on longer-lasting antibody responses 
must be restricted to children of an age group consist-
ent with the timeframe to be sampled [53, 57], and such 
groups may have atypical exposure, complicating inter-
pretation of results.
Serological assays for population screening will need to 
be sufficiently low cost to enable a statistically significant 
population size to be sampled. Savings in better target-
ing of anti-malarial resources could justify the cost. It is 
likely that such a test would be coupled with follow-up 
by intensive case management interventions, MDA or 
FSAT, with targeting guided by the population screening 
results. This market is currently poorly served by exist-
ing technologies, and population screening is rarely per-
formed outside of pilot and research studies. The market 
is, therefore, unpredictable but could evolve if suitable 
assays were available.
Clinical research and therapeutic efficacy monitoring
Assays used as reference standards in monitoring of 
drug therapy must provide a result that distinguishes 
between all species, enables quantitation and monitor-
ing of parasite density changes, has high consistency, 
and has a LLOD sufficiently low to enable tracking of 
parasite density below that associated with symptoms. 
However, these assays need not be capable of returning 
a result in time for immediate treatment if case man-
agement diagnostics (e.g. RDTs) are also available. This 
market segment is more difficult to define but is distin-
guishable from the needs of control or elimination pro-
gramme implementation. Required LLODs depend on 
the aims of the research, but requirements for quanti-
tative tests to address the needs of WHO recommen-
dations for therapeutic efficacy monitoring sites are 
well-defined [58]. This market segment is limited in scale, 
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but of significant public health importance if the develop-
ment of drug resistance is to be monitored routinely by 
national malaria programmes, and drug policy is to be 
sufficiently responsive to early changes in patterns of effi-
cacy. More broadly, standardization of tests used in clini-
cal research would improve the comparability of malaria 
trials across space and time—currently poor due to lack 
of adherence to common standards [59].
Cross‑checking for microscopy quality control
Case management diagnosis in endemic settings con-
tinues to rely extensively upon light microscopy, with 
reported microscopy use increasing to 197 million 
microscopic examinations in 2013 [1]. To be reliable, 
light microscopy requires high levels of quality assur-
ance, including slide cross-checking (validation) to moni-
tor microscopist performance post hoc. Cross-checking 
is frequently poorly performed or absent due to limita-
tions of technician skill, training, and time to perform 
the validation [60]. A potential market exists for an auto-
mated cross-checking platform that could process large 
numbers of Romanowski-stained light microscopy slides 
(Giemsa, Field’s or JSB Stain) at a central location and 
provide results that are highly consistent and of similar 
LLOD to expert microscopy. If such a device was suf-
ficiently portable and cheap, it might replace manual 
malaria microscopy and change the use-case to include 
case management, but would still require some form of 
on-going validation.
An assay to validate microscopy technician perfor-
mance must be capable of quantitation and species dif-
ferentiation, and operate on slides that have been read 
previously and are not in current practice routinely 
cover-slipped. While the TPP of such an assay may over-
lap with that for case management or other tools, the 
requirement to be near point-of-care is removed. Auto-
mated slide feed would have clear advantages.
As with the market for a quantitative test for drug 
monitoring, the market size for such a test is limited, but 
the absence of a tool that fits the requirement of the mar-
ket is a significant current impediment to ensuring the 
quality of malaria microscopy [60, 61]. The WHO recom-
mends a minimum sample size for cross-checking of 10 
randomly selected slides per month for a clinical labora-
tory; five slides reported as low density, and five reported 
as negative [30]. This could presumably be increased if 
an automated validation system were available. Should 
a digital automated slide reader of sufficient quality be 
developed, it will still be dependent on systems being in 
place for feedback, supervision and retraining. Estimat-
ing the true market for such a system is therefore some-
what difficult, and will depend also on the persistence of 
microscopy as a major platform for malaria diagnosis.
Non‑endemic country markets distinguished primarily 
by resource availability
The diagnostic market in non-endemic settings is essen-
tially case management for febrile returned travelers. It is 
highly diverse and generally better-resourced than other 
market segments considered. Testing is likely to be two-
tiered: there is a requirement for rapid testing at point 
of care to guide immediate management, and for tests 
that provide high sensitivity at low parasite densities, 
on the basis that patients are non-immune and may pre-
sent clinically early in an infection course. Such require-
ments may be addressed initially by a rapid near-patient 
test, with confirmation by a test with high sensitivity (e.g. 
PCR), or by a highly sensitive near-patient test, such as 
LAMP [62], as resource constraints are less of an issue. 
The use of highly sensitive tests may also be driven by 
other imperatives such as litigation and public expec-
tations, and by lack of confidence in point of care tests 
performed by technicians with very limited malaria expe-
rience. Malaria infections in developed countries are also 
generally more closely monitored, with more emphasis 
on parasite quantitation [63, 64].
A special case exists where screening of immigrant 
populations or other travelers is desired to avoid re-
introduction and resumption of transmission [50, 65]. 
This requires parasite screening tools as described ear-
lier, with a high probability of detecting very low parasite 
density (asymptomatic) infections, returning results in 
a sufficiently timely manner to enable identification and 
treatment of positive cases and to minimize the prob-
ability of onward transmission while awaiting results. A 
further area of need includes screening tools for donated 
blood–blood bank screening is a complex area with 
requirements varying with endemicity, travel history, and 
availability of alternative sources, and is not addressed 
further here.
Estimating market size
The diagnostic market segments and corresponding 
TPPs discussed above (examples available in Additional 
file  1: Annex S1) are in many respects parts of a con-
tinuum: the performance requirements for the various 
markets often overlap, and most current diagnostic plat-
forms imperfectly fit any profile, but are relevant to more 
than one. Thus, determining the place of a new platform 
in malaria diagnosis requires value judgments on the 
importance of reaching some performance requirements 
while falling short of others. The relative importance 
of aspects of product performance also vary between 
national programs and epidemiological settings. Some 
programs are able to maintain high quality light micros-
copy for case management at a peripheral level [60, 61, 
66], while some struggle to support microscopy of safe 
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quality more centrally [31–34]. Some programmes may 
operate in areas where populations are clustered around 
well-serviced nodes, while in others malaria may be con-
fined to remote areas and predominantly mobile popula-
tions [67].
Performance, cost, and ease-of-use requirements exist 
that determine the usefulness of a given diagnostic tech-
nology. Examples of benchmarks set by current prod-
ucts that determine market entry criteria can be seen in 
case management, screening and non-endemic markets. 
These are addressed in turn below. A paucity of accu-
rate data and dependence of future markets on changes 
in strategy development and donor funding renders the 
size of malaria diagnostics markets difficult to estimate 
and predict. For example, at what level does a population 
very close to malaria elimination, in which malaria case 
management no longer a priority, cease to be a market 
for case-management diagnostics? And when will elimi-
nation screening be introduced at scale, if at all?
Case management
The annual diagnostic need in case management of acute 
fever in populations at risk of malaria could be several 
times higher than the market suggested based on the 
319 million RDTs sold by manufacturers and 197 million 
microscopic examinations performed [1]. The market is 
restricted by availability of financial resources, trained 
staff, and competing public health priorities; it will there-
fore vary with the costs of the assays used. However, 
access is still inadequate across many endemic countries, 
illustrating the room for growth in this market. Further, 
the definition of ‘suspected malaria’ is obviously fluid: as 
example, a few hundred million people in China are at 
theoretical risk of malaria but the level of suspicion there, 
and consequently the likelihood of testing, differs in com-
parison to a high-transmission country.
High prevalence countries commonly have nearly the 
entirety of their populations living in at-risk areas. These 
countries also tend to be characterized by relatively 
resource-poor health systems and often have limited 
data available on diagnostic practice, or on quality assur-
ance programs for these tests. Microscopy and RDT use 
is mixed: Burkina Faso, for example, used 0.57 million 
microscopy slides and 4.02 million RDTs in 2011 [10]. 
Many febrile patients did not receive a diagnosis [68], 
indicating that the total size of the potential market is 
well above the current level of use. The mix of private and 
public sector diagnosis also varies, with private sector 
market data even harder to obtain. Private sector health 
access varies greatly between countries, but likely con-
tributes little to overall diagnostic numbers, due to a low 
use of malaria diagnostics in this sector [69].
Medium-prevalence countries (as defined by WHO) 
occur predominantly in South and Southeast Asia, and 
are the regions most affected by malaria after Africa with 
29 million reported cases in the 2011–2012 season [70]. 
The majority of these populations live in low transmis-
sion areas, while a small proportion live in high trans-
mission areas. Overall, 2.1 billion people in South and 
Southeast Asia live in areas at theoretical risk of malaria 
infection, approximately 62 % of the region’s total popu-
lation. Microscopy is most often used in these regions. 
India, with its high at-risk population, dominates glob-
ally in number of microscopy slides examined each year; 
over 120 million in 2013 [1]. However, with only 2 % of 
these being parasite-positive, the market is fragile, and a 
decision to restrict testing or transition to RDTs as the 
primary diagnostic could remove much of the global 
microscopy market. Continuation at current scale in the 
face of such low slide positive rates must be uncertain, 
although increased emphasis on elimination may serve 
to increase market size. Microscopy rates are relevant for 
introduction of technologies aimed at improving micros-
copy quality assurance, based on an assumption that 
microscopy persists for reasons not served by RDTs, such 
as parasite quantitation.
Non-endemic country markets are essentially based on 
case-management needs of travelers (and to some extent 
screening for blood donation). Again, reliable data is not 
readily available. While malaria positive rates may be 
collated, data on tests performed are less accessible. As 
an example, we can consider the case management mar-
ket in the United Kingdom (UK) and Western Europe. 
Between 1987 and 2006, 39,300 cases of malaria were 
reported to the UK’s Malaria Reference Laboratory [71]. 
With some extrapolation, a general idea of market size 
can be gained. Data on actual cases suggests about 10,000 
cases of malaria each year in all of Western Europe, with 
about 70 % of these concentrated in the UK, France, Ger-
many and Italy [72]. Assuming the positivity rate of 5 % 
is broadly accurate, it can be assumed that approximately 
200,000 tests are performed. Much will depend on the 
pool from which immigrants arise and the areas to which 
nationals travel. While overall numbers appear small, the 
value of the market in monetary terms is more signifi-
cant, as far greater resources are available for individual 
health care.
Market for parasite screening tests
The majority of the populations in low-prevalence coun-
tries (e.g. Cambodia, the Philippines, Swaziland) live in 
areas of low transmission or are malaria-free, and trans-
mission is highly heterogeneous [67, 73, 74]. As an exam-
ple, 28 of the 80 provinces were declared malaria-free 
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in the Philippines in 2011 [75] but prevalence in febrile 
cases still reaches 49  % in some areas against a back-
ground national rate of 4  %. A mix of diagnostic and 
screening practices is therefore likely to be required, 
including measures to prevent or reduce reintroduction 
from transmission to non-transmission areas, and high 
surveillance levels in areas where relatively little trans-
mission persists. However, the market size for each of 
these applications is dependent on the priorities of the 
national programme, local priorities, and funding sup-
port (e.g. elimination in low-transmission areas versus 
reducing mortality and morbidity in high-burden areas), 
and so will remain unpredictable.
The WHO lists 20 countries as being in the pre-elimi-
nation and elimination phases, and nine preventing rein-
troduction of malaria [4]. Despite these achievements, 
3.3 billion people were at risk of contracting malaria and 
developing disease in 2014, with 1.2 billion being consid-
ered high-risk [1]. Targeted screening for asymptomatic 
infections is likely to have a potential role in accelerating 
elimination and reducing the probability of reintroduc-
tion and resurgent transmission in these populations. As 
FSAT strategies and screening of immigrant populations 
remain limited by a lack of appropriate tools, and policies 
on wide-scale interventions (e.g. MDA) versus focused 
activity are still debated, these estimates of market size 
need to be treated with caution. Much will depend on 
priorities of large funding bodies, the availability of 
appropriate technologies, and the outcomes of future 
studies on impact of screening for low-density infections 
on interruption of transmission.
Finally, a small but more predictable screening mar-
ket exists in countries conducting malaria indicator 
surveys (MIS) or similar surveys of large populations, 
where highly sensitive tests may be required to determine 
realistic prevalence in areas where low-parasite density 
infections are common. Typical MIS surveys sample 
about 7000–10,000 cases (e.g. Zambia) [12], but occur at 
irregular intervals.
Lastly, non-endemic country markets are typically 
characterized by much higher available resources, and 
an immunologically-naive population. Screening is still 
commonly based on microscopy, either initially or as a 
backup to RDTs [63, 64]. Total cases tested are very low 
for population size, with approximately 38,000 cases 
tested out of a population of 317 million in the UK will 
be spread across a wide range of health care access points 
(figure derived from positivity rates in the UK, based on 
unpublished analysis conducted by the authors in malaria 
diagnostics market analysis and report). Therefore, while 
resources are relatively high, the investment required per 
case diagnosed will be very high if a diagnostic platform 
is to be readily available across primary care settings, 
so fixed and variable costs are still relevant to market 
acceptability.
Conclusion
Diagnostic markets can thus be categorized accord-
ing to their role in overall malaria management, and the 
specific performance characteristics required to address 
them. Such market segmentation is necessary to under-
stand whether a new technology is likely to be useful in 
malaria diagnosis, and if so, what market size might be 
expected. This paper suggests six distinct markets, to 
which diagnostic platforms can be applied. These vary in 
how adequately they are served by current technologies. 
While each of these markets is potentially compelling 
from a public health standpoint, size and scale are highly 
variable and continue to evolve. Consequently, returns 
on investment in research and development are unpre-
dictable, highlighting the need for potentially significant 
donor involvement or the introduction of novel business 
models to overcome prohibitive economics. These invest-
ments need to be targeted to areas with real technology 
gaps, and where sufficient interest exists to sustain manu-
facture and justify the targeting of relatively scanty devel-
opment funding.
Furthermore, given the rather specific applications, 
a well-defined set of stakeholders will need to be on 
board for the successful introduction and scaling of any 
new technology to these markets. Though the potential 
impact is quite significant, potential innovators in this 
space need to be aware of these challenges, and thor-
oughly understand the implications of the associated 
target product profiles before proceeding. Limited fund-
ing for research and development needs to be directed to 
technologies that are likely to address real areas of tech-
nological need (distinguishing from unrelated program-
matic need). Assessing these gaps requires a realistic view 
of the effectiveness and shortfalls of existing technolo-
gies, rather than reiteration of the burden of malaria and 
fever cases. Current technologies are often very effective, 
the gaps can lie elsewhere.
Abbreviations
FSAT: focal screen and treat; LAMP: loop-mediated isothermal amplification; 
LLOD: lower limit of detection; MDA: Mass Drug Administration; MIS: malaria 
indicator surveys; PCR: polymerase chain reaction; POCT: point of care testing; 
RDT: routine diagnostics tests; TPP: target product profiles; WHO: World Health 
Organization.
Additional file
Additional file 1: Annex S1. Example target product profiles for malaria 
diagnostic markets.
Page 10 of 12Bell et al. Malar J  (2016) 15:406 
Authors’ contributions
DB guided review concept and contributed to writing of manuscript. AF 
and DB conducted preliminary research and MH, JB, and CM conducted 
background research and co-wrote final manuscript. All authors contributed 
significantly to the content and provided approval of the final manuscript. All 
authors read and approved the final manuscirpt.
Author details
1 Global Good Fund/Intellectual Ventures Laboratory, 3150 139th Ave SE, Belle-
vue, WA 98005, USA. 2 Concept Foundation, Geneva, Switzerland. 3 iSense, LLC, 
Cambridge, MA, USA. 4 Independent Consultant, Seattle, USA. 5 International 
Training and Education Center for Health (I-TECH), Gaborone, Botswana. 
Acknowledgements
The authors gratefully acknowledge Bill and Melinda Gates for their sponsor-
ship through the Intellectual Ventures Global Good Fund.
Competing interests
DB and CM receive salary or consulting fees from an organization (Global 
Good Fund) engaged in development of diagnostic tests, including tests 
intended for malaria.
Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or 
analysed during the current study.
Funding
An original report by DB and AF on which this document is based was pro-
vided by Global Good Fund to the Foundation for Innovative New Diagnostics.
Received: 6 July 2016   Accepted: 28 July 2016
References
 1. WHO. World malaria report 2014. Geneva: World Health Organization; 
2014. http://www.who.int/entity/malaria/publications/world_malaria_
report_2014/wmr-2014-no-profiles.pdf?ua=1. Accessed 2016.
 2. Amexo M, Tolhurst R, Barnish G, Bates I. Malaria misdiagnosis: effects on 
the poor and vulnerable. Lancet. 2004;364:1896.
 3. StJohn A, Price CP. Existing and emerging technologies for point-of-care 
testing. Clin Biochem Rev. 2014;35:155–67.
 4. WHO. World malaria report 2015. Geneva: World Health 
Organization; 2015. http://apps.who.int/iris/bitstr
eam/10665/200018/1/9789241565158_eng.pdf. Accessed 2016.
 5. Thiam S, Thior M, Faye B, Ndiop M, Diouf ML, Diouf MB, et al. Major 
reduction in anti-malarial drug consumption in Senegal after nation-wide 
introduction of malaria rapid diagnostic tests. PLoS ONE. 2011;6:e18419.
 6. PATH. Staying the course? Malaria research and development in a time of 
economic uncertainty. PATH; 2011. http://www.malariavaccine.org/files/
RD-report-June2011.pdf.
 7. Roll back malaria partnership. eliminating malaria: learning from the 
past, looking forward. Roll Back Malaria Partnership; 2011. Report No.: 9: 
http://www.archiverbm.rollbackmalaria.org/ProgressImpactSeries/docs/
report9-en.pdf. Accessed 2016.
 8. malERA Consultative Group on Diagnoses and Diagnostics. A research 
agenda for malaria eradication: diagnoses and diagnostics. PLoS Med. 
2011;8:e1000396.
 9. Elahi R, Mohon A, Khan W, Haque R, Alam M. Performance of a HRP-2/
pLDH based rapid diagnostic test at the Bangladesh–India–Myanmar 
border areas for diagnosis of clinical malaria. Malar J. 2013;12:378.
 10. WHO. World malaria report 2012. Geneva: World Health 
Organization; 2012. http://www.who.int/iris/bitstr
eam/10665/78945/1/9789241564533_eng.pdf. Accessed May 2016.
 11. World Health Organization. World malaria report 2011. Geneva: World 
Health Organization; 2011. http://www.who.int/malaria/world_malaria_
report_2011/WMR2011_noprofiles_lowres.pdf?ua=1. Accessed 2016.
 12. Zambia Ministry of Health (MOH). Zambia National Malaria Indicator 
Survey 2010. Lusaka: Zambia Ministry of Health; 2010. http://www.nmcc.
org.zm/files/FullReportZambiaMIS2010_001.pdf.
 13. WHO. Parasitological confirmation of malaria diagnosis: report of a 
WHO technical consultation, Geneva, 6–8 October 2009. Geneva: World 
Health Organization; 2010. p. 67. http://www.whqlibdoc.who.int/publica-
tions/2010/9789241599412_eng.pdf. Accessed 2016.
 14. Singh N, Bharti P, Singh M, Mishra S, Shukla M, Sharma R, et al. Compara-
tive evaluation of bivalent malaria rapid diagnostic tests versus traditional 
methods in field with special reference to heat stability testing in central 
India. PLoS ONE. 2013;8:e58080.
 15. Jang J, Cho C, Han E, An SS, Lim C. pLDH level of clinically isolated Plas-
modium vivax and detection limit of pLDH based malaria rapid diagnostic 
test. Malar J. 2013;12:181.
 16. Okell LC, Ghani AC, Lyons E, Drakeley CJ. Submicroscopic infection in 
Plasmodium falciparum-endemic populations: a systematic review and 
meta-analysis. J Infect Dis. 2009;200:1509.
 17. Yukich JO, Bennett A, Albertini A, Incardona S, Moonga H, Chisha Z, et al. 
Reductions in artemisinin-based combination therapy consumption after 
the nationwide scale up of routine malaria rapid diagnostic testing in 
Zambia. Am J Trop Med Hyg. 2012;87:437–46.
 18. Abba K, Deeks JJ, Olliaro P, Naing CM, Jackson SM, Takwoingi Y, et al. Rapid 
diagnostic tests for diagnosing uncomplicated P. falciparum malaria in 
endemic countries. Cochrane Database Syst. Rev. 2011;CD008122
 19. Counihan H, Harvey SA, Sekeseke-Chinyama M, Hamainza B, Banda R, 
Malambo T, et al. Community health workers use malaria rapid diagnostic 
tests (RDTs) safely and accurately: results of a longitudinal study in Zam-
bia. Am J Trop Med Hyg. 2012;87:57–63.
 20. WHO-FIND-CDC-TDR. Malaria rapid diagnostic test performance: 
results of WHO product testing of malaria RDTs: round 4 (2012). 
Geneva: World Health Organization; 2012. http://www.who.int/iris/
bitstream/10665/77748/1/9789241504720_eng.pdf. Accessed May 
2016.
 21. WHO-FIND-CDC-HTD. Methods manual for product testing of malaria 




 22. Yeboah-Antwi K, Pilingana P, Macleod WB, Semrau K, Siazeele K, Kalesha 
P, et al. Community case management of fever due to malaria and pneu-
monia in children under five in Zambia: a cluster randomized controlled 
trial. PLoS Med. 2010;7:e1000340.
 23. Faucher J-F, Makoutode P, Abiou G, Beheton T, Houze P, Ouendo E, et al. 
Can treatment of malaria be restricted to parasitologically confirmed 
malaria? A school-based study in Benin in children with and without 
fever. Malar J. 2010;9:104.
 24. Senn N, Rarau P, Manong D, Salib M, Siba P, Robinson LJ, et al. Rapid 
diagnostic test-based management of malaria: an effectiveness study in 
Papua New Guinean infants with Plasmodium falciparum and Plasmo-
dium vivax malaria. Clin Infect Dis. 2012;54:644–51.
 25. Mtove G, Hendriksen I, Amos B, Mrema H, Mandia V, Manjurano A, et al. 
Treatment guided by rapid diagnostic tests for malaria in Tanzanian 
children: safety and alternative bacterial diagnoses. Malar J. 2011;10:290.
 26. D’Acremont V, Malila A, Swai N, Tillya R, KahamaMaro J, Lengeler C, et al. 
Withholding antimalarials in febrile children who have a negative result 
for a rapid diagnostic test. Clin Infect Dis. 2010;51:506–11.
 27. Ansah EK, Narh-Bana S, Epokor M, Akanpigbiam S, Quartey AA, Gyapong 
J, et al. Rapid testing for malaria in settings where microscopy is available 
and peripheral clinics where only presumptive treatment is available: a 
randomised controlled trial in Ghana. BMJ. 2010;340:c930.
 28. Bell B, Wongsrichanalai C, Barnwell JW. Ensuring quality and access for 
malaria diagnosis: how can it be achieved? Nat Rev Microbiol. 2006;4:682.
 29. Gamboa D, Ho M-F, Bendezu J, Torres K, Chiodini PL, Barnwell JW, et al. A 
large proportion of P. falciparum isolates in the Amazon region of Peru 
lack pfhrp2 and pfhrp3: implications for malaria rapid diagnostic tests. 
PLoS ONE. 2010;5:e8091.
 30. WHO. Malaria microscopy quality assurance manual—Version 1. Geneva: 
World Health Organization; 2009. http://www.who.int/malaria/publica-
tions/atoz/mmicroscopy_qam/en/. Accessed 2014.
Page 11 of 12Bell et al. Malar J  (2016) 15:406 
 31. O’Meara WP, Mckenzie FE, Magill AJ, Forney JR, Permpanich B, Lucas C, 
et al. Sources of variability in determining malaria parasite density by 
microscopy. Am J Trop Med Hyg. 2005;73:593–8.
 32. Kahama-Maro J, D’Acremont V, Mtasiwa D, Genton B, Lengeler C. Low 
quality of routine microscopy for malaria at different levels of the health 
system in Dar es Salaam. Malar J. 2011;10:332.
 33. Harchut K, Standley C, Dobson A, Klaassen B, Rambaud-Althaus C, Althaus 
F, et al. Over-diagnosis of malaria by microscopy in the Kilombero Valley, 
Southern Tanzania: an evaluation of the utility and cost-effectiveness of 
rapid diagnostic tests. Malar J. 2013;12:159.
 34. Ngasala B, Mubi M, Warsame M, Petzold MG, Massele AY, Gustafsson LL, 
et al. Impact of training in clinical and microscopy diagnosis of childhood 
malaria on antimalarial drug prescription and health outcome at primary 
health care level in Tanzania: a randomized controlled trial. Malar J. 
2008;7:199.
 35. McMorrow ML, Aidoo M, Kachur SP. Malaria rapid diagnostic tests in 
elimination settings—can they find the last parasite? Clin Microbiol 
Infect. 2011;17:1624–31.
 36. Hoyer S, Nguon S, Kim S, Habib N, Khim N, Sum S, et al. Focused screen-
ing and treatment (FSAT): a PCR-based strategy to detect malaria parasite 
carriers and contain drug resistant P. falciparum, Pailin, Cambodia. PLoS 
ONE. 2012;7:e45797.
 37. Collins WE, Jeffery GM. A retrospective examination of sporozoite- and 
trophozoite-induced infections with Plasmodium falciparum: develop-
ment of parasitologic and clinical immunity during primary infection. Am 
J Trop Med Hyg. 1999;61:4–19.
 38. Collins WE, Jeffery GM. A retrospective examination of mosquito infection 
on humans infected with Plasmodium falciparum. Am J Trop Med Hyg. 
2003;68:366–71.
 39. Collins WE, Jeffery GM, Roberts JM. A retrospective examination of ane-
mia during infection of humans with Plasmodium vivax. Am J Trop Med 
Hyg. 2003;68:410–2.
 40. Roper C, Elhassan IM, Hviid L, Giha H, Richardson W, Babiker H, et al. 
Detection of very low level Plasmodium falciparum infections using the 
nested polymerase chain reaction and a reassessment of the epidemiol-
ogy of unstable malaria in Sudan. Am J Trop Med Hyg. 1996;54:325–31.
 41. Toma H, Kobayashi J, Vannachone B, Arakawa T, Sato Y, Nambanya S, et al. 
A field study on malaria prevalence in southeastern Laos by polymerase 
chain reaction assay. Am J Trop Med Hyg. 2001;64:257–61.
 42. Alves FP, Durlacher RR, Menezes MJ, Krieger H, Silva LHP, Camargo EP. 
High prevalence of asymptomatic Plasmodium vivax and Plasmodium 
falciparum infections in native Amazonian populations. Am J Trop Med 
Hyg. 2002;66:641–8.
 43. Zakeri S, Najafabadi S, Zare A, Djadid N. Detection of malaria parasites by 
nested PCR in south-eastern Iran: evidence of highly mixed infections in 
Chahbahar District. Malar J. 2002;1:2.
 44. Manjurano A, Okell L, Lukindo T, Reyburn H, Olomi R, Roper C, et al. Asso-
ciation of sub-microscopic malaria parasite carriage with transmission 
intensity in north–eastern Tanzania. Malar J. 2011;10:370.
 45. Bell DR, Wilson DW, Martin LB. False-positive results of a Plasmodium 
falciparum histidine-rich protein 2-detecting malaria rapid diagnostic 
test due to high sensitivity in a community with fluctuating low parasite 
density. Am J Trop Med Hyg. 2005;73:199–203.
 46. Steenkeste N, Incardona S, Chy S, Duval L, Ekala M-T, Lim P, et al. Towards 
high-throughput molecular detection of Plasmodium: new approaches 
and molecular markers. Malar J. 2009;8:86.
 47. Bell D, Go R, Miguel C, Walker J, Cacal L, Saul A. Diagnosis of malaria in 
a remote area of the Philippines: comparison of techniques and their 
acceptance by health workers and the community. Bull World Health 
Organ. 2001;79:933–41.
 48. Okell LC, Bousema T, Griffin JT, Ouédraogo AL, Ghani AC, Drakeley CJ. 
Factors determining the occurrence of submicroscopic malaria infections 
and their relevance for control. Nat Commun. 2012;3:1237.
 49. Imwong M, Nguyen TN, Tripura R, Peto TJ, Lee SJ, Lwin KM, et al. The 
epidemiology of subclinical malaria infections in South-East Asia: findings 
from cross-sectional surveys in Thailand-Myanmar border areas, Cambo-
dia, and Vietnam. Malar J. 2015;14:381.
 50. Tatarsky A, Aboobakar S, Cohen JM, Gopee N, Bheecarry A, Moonasar D, 
et al. Preventing the reintroduction of malaria in Mauritius: a program-
matic and financial assessment. PLoS ONE. 2011;6:e23832.
 51. Collins WE, Jeffery GM, Roberts JM. A retrospective examination of 
the effect of fever and microgametocyte count on mosquito infec-
tion on humans infected with Plasmodium vivax. Am J Trop Med Hyg. 
2004;70:638–41.
 52. Hopkins H, Asiimwe C, Bell D. Access to antimalarial therapy: accurate 
diagnosis is essential to achieving long term goals. BMJ. 2009;339:324.
 53. Bretscher M, Supargiyono S, Wijayanti M, Nugraheni D, Widyastuti A, Lobo 
N, et al. Measurement of Plasmodium falciparum transmission intensity 
using serological cohort data from Indonesian school children. Malar J. 
2013;12:21.
 54. Drakeley CJ, Corran PH, Coleman PG, Tongren JE, Mcdonald SLR, Carneiro 
I, et al. Estimating medium- and long-term trends in malaria transmission 
by using serological markers of malaria exposure. Proc Natl Acad Sci USA. 
2005;102:5108–13.
 55. Bejon P, Turner L, Lavstsen T, Cham G, Olotu A, Drakeley CJ, et al. Sero-
logical evidence of discrete spatial clusters of Plasmodium falciparum 
parasites. PLoS ONE. 2011;6:e21711.
 56. Bousema T, Youssef RM, Cook J, Cox J, Alegana VA, Amran J, et al. Sero-
logic markers for detecting malaria in areas of low endemicity, Somalia, 
2008. Emerg Infect Dis. 2010;16:392–9.
 57. Stewart L, Gosling R, Griffin J, Gesase S, Campo J, Hashim R, et al. Rapid 
assessment of malaria transmission using age-specific sero-conversion 
rates. PLoS ONE. 2009;4:e6083.
 58. WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: 
World Health Organization; 2009. http://www.whqlibdoc.who.int/publi-
cations/2009/9789241597531_eng.pdf?ua=1. Accessed 2016.
 59. WHO. Microscopy for the detection, identification and quantification of malaria 
parasites on stained thick and thin blood films in research settings—proce-
dure. Geneva: World Health Organization; 2015. http://www.wwarn.org/sites/
default/files/attachments/procedures/microscopy_eng.pdf. Accessed 2016
 60. Ashraf S, Kao A, Hugo C, Christophel EM, Fatunmbi B, Luchavez J, et al. 
Developing standards for malaria microscopy: external competency 
assessment for malaria microscopists in the Asia–Pacific. Malar J. 
2012;11:352.
 61. Khan MA, Walley JD, Munir MA, Khan MA, Khokar NG, Tahir Z, et al. District 
level external quality assurance (EQA) of malaria microscopy in Pakistan: 
pilot implementation and feasibility. Malar J. 2011;10:45.
 62. Polley SD, González IJ, Mohamed D, Daly R, Bowers K, Watson J, et al. 
Clinical evaluation of a loop-mediated amplification kit for diagnosis of 
imported malaria. J Infect Dis. 2013;208:637–44.
 63. Lalloo DG, Shingadia D, Pasvol G, Chiodini PL, Whitty CJ, Beeching NJ, 
et al. UK malaria treatment guidelines. J Infect. 2007;54:111–21.
 64. CDC. Treatment of malaria (guidelines for Clinicians). 2013. http://www.
cdc.gov/malaria/resources/pdf/clinicalguidance.pdf. Accessed 2014.
 65. Sultan DM, Khalil MM, Abdouh AS, Doleh WF, Al Muthanna AAM. 
Imported malaria in United Arab Emirates: evaluation of a new 
DNA extraction technique using nested PCR. Korean J Parasitol. 
2009;47:227–33.
 66. Nateghpour M, Edrissian G, Raeisi A, Motevalli-Haghi A, Farivar L, Mohseni 
G, et al. The role of malaria microscopy training and refresher training 
courses in malaria control program in Iran during 2001–2011. Iran J 
Parasitol. 2012;7:104–9.
 67. Delacollette C, D’Souza C, Christophel E, Thimasarn K, Abdur R, Bell D, 
et al. Malaria trends and challenges in the Greater Mekong Subregion. 
Southeast Asian J Trop Med Public Health. 2009;40:674–91.
 68. WHO. World malaria report 2013. Geneva: World Health Organization; 
2013. http://www.who.int/entity/malaria/publications/world_malaria_
report_2013/wmr2013_no_profiles.pdf?ua=1.
 69. Albertini A, Djalle D, Faye B, Gamboa D, Luchavez J, Mationg ML, et al. 
Preliminary enquiry into the availability, price and quality of malaria 
rapid diagnostic tests in the private health sector of six malaria-endemic 
countries. Trop Med Int Health. 2012;17:147–52.
 70. Roll Back Malaria Partnership. Defeating malaria in Asia, the Pacific, Ameri-
cas, Middle East, and Europe; 2012. http://www.archiverbm.rollbackma-
laria.org/ProgressImpactSeries/docs/report12.pdf.
 71. Smith AD, Bradley DJ, Smith V, Blaze M, Behrens RH, Chiodini PL, et al. 
Imported malaria and high risk groups: observational study using UK 
surveillance data 1987–2006. BMJ. 2008;337:a120.
 72. Askling HH, Bruneel F, Burchard G, Castelli F, Chiodini PL, Grobusch MP, 
et al. Management of imported malaria in Europe. Malar J. 2012;11:328.
Page 12 of 12Bell et al. Malar J  (2016) 15:406 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 73. Simon C, Moakofhi K, Mosweunyane T, Jibril H, Nkomo B, Motlaleng M, 
et al. Malaria control in Botswana, 2008-2012: the path towards elimina-
tion. Malar J. 2013;12:458.
 74. Kobayashi T, Chishimba S, Shields T, Hamapumbu H, Mharakurwa S, 
Thuma PE, et al. Temporal and spatial patterns of serologic responses to 
Plasmodium falciparum antigens in a region of declining malaria trans-
mission in southern Zambia. Malar J. 2012;11:438.
 75. Global Health Group. Eliminating malaria in the Philippines; 2013. http://
www.globalhealthsciences.ucsf.edu/sites/default/files/content/ghg/
country-briefings/asia-pacific/Philippines_2013.pdf. Accessed 2016.
